DOCSLIB.ORG

Phenoxymethylpenicillin 125Mg & 250Mg OS KENT PIL (V3P2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenoxymethylpenicillin 125Mg & 250Mg OS KENT PIL (V3P2) CP.PEN.JNT.So.Sp.AT.V3P2 PATIENT INFORMATION LEAFLET Adults including the elderly and children over Blood P713/4 12 years • problems with blood clotting (unusual bleeding PHENOXYMETHYLPENICILLIN 250mg to 500mg every six hours (one to two 5ml or bruising) 125mg/5ml AND 250mg/5ml ORAL SOLUTION spoonfuls of 250mg/5ml) • infections or fever (may be caused by low Prophylactic use: 250mg twice daily is white blood cells) Read all of this leaflet carefully before you start taking this medicine because it contains recommended for long term prophylaxis of • anaemia (may cause lack of energy or information for you. rheumatic fever (one 5ml spoonful of 250mg/5ml) tiredness) • Keep this leaflet. You may need to read it again. Kidney • If you have further questions, ask your doctor or pharmacist (chemist). Children • kidney problems, which might cause blood in • This medicine has been prescribed for you only. Do not pass it on to others. It may harm Infants (up to 1 year): 62.5mg every six hours the urine or reduced amounts of urine them, even if their signs of illness are the same as yours. 1 - 5 years: 125mg every six hours (one 5ml Liver • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side spoonful of 125mg/5ml) • jaundice - yellowing of skin or whites of the eyes effects not listed in this leaflet. See section 4. 6 - 12 years: 250mg every six hours (one 5ml spoonful of 250mg/5ml or two 5ml spoonfuls of If any of the side effects get serious, or if you WHAT IS IN THIS LEAFLET 125mg/5ml) notice any side effect not listed in this leaflet, you 1. What Phenoxymethylpenicillin Oral Solution is and what it is used for should contact your doctor or pharmacist. 2. What you need to know before you take Phenoxymethylpenicillin Oral Solution When to take your medicine 3. How to take Phenoxymethylpenicillin Oral Solution Phenoxymethylpenicillin should be given in Reporting of side effects 4. Possible side effects divided doses (4 times a day) or as directed by If you get any side effects, talk to your doctor or 5. How to store Phenoxymethylpenicillin Oral Solution your doctor. Take your medicine on an empty pharmacist or nurse. This includes any possible 6. Contents of the pack and other information stomach either half an hour before a meal or at side effects not listed in this leaflet. You can also least three hours after a meal. report side effects directly via the yellow card scheme at www.mhra.gov.uk/yellowcard or WHAT PHENOXYMETHYLPENICILLIN • Oral Typhoid vaccine (penicillin can stop this How long to take your medicine for search for MHRA Yellow Card in the Google Play ORAL SOLUTION IS AND WHAT IT IS from working) Keep taking this medicine until your doctor tells or Apple App Store. By reporting side effects you USED FOR • Some other antibiotics (Tetracycline, you to stop. Do not stop taking it just because can help provide more information on the safety 1. Erythromycin, Chloramphenicol and Neomycin) you feel better. of this medicine. The name of your medicine is Phenoxymethylpenicillin 125mg/5ml and Taking with food and drink If you take more Phenoxymethylpenicillin HOW TO STORE 250mg/5ml Oral Solution. It is available in two Take your medicine on an empty stomach either Oral Solution than you should PHENOXYMETHYLPENICILLIN ORAL strengths as a powder for reconstitution. The half an hour before a meal or at least three hours If you accidentally take too much SOLUTION powder for reconstitution is prepared by the after a meal. Guar gum can cause reduced Phenoxymethylpenicillin Oral Solution, contact 5. pharmacist before dispensing by adding water to absorption of phenoxymethylpenicillin. Your your doctor or pharmacist who will recommend KEEP OUT OF THE SIGHT AND REACH OF the powder to give 100ml of oral solution. The doctor will advise you about this. what action you should take. CHILDREN strength you are given will be decided by your doctor. Pregnancy and breast-feeding If you forget to take Phenoxymethylpenicillin Expiry Date Phenoxymethylpenicillin, the active ingredient, is If you are pregnant or breast-feeding, think you Oral Solution Do not use your medicine after the expiry date an antibiotic, which belongs to a group of may be pregnant or are planning to have a baby, If you do forget to take a dose of stated on the label. The expiry date refers to the medicines called penicillins, which are used to ask your doctor or pharmacist for advice before Phenoxymethylpenicillin Oral Solution at the last day of the month. kill bacteria that cause infections in your body. taking this medicine. correct time, take it as soon as you remember, then carry on as before. Do not take a double Storage Conditions Your medicine is used to: Phenoxymethylpenicillin Oral Solution dose to make up for a forgotten dose. Store in the original package. Keep the bottle • treat bacterial infections of the ear, throat, contains Sucrose, Potassium, Sodium tightly closed. respiratory tract, skin and soft tissues benzoate, Sodium, E124 & E110 If you stop taking your medicine Dry powder: Store in a dry place below 25°C. • prevent infections such as rheumatic fever or Sucrose If you stop taking the medicine before your Protect from light. chorea recurring. Phenoxymethylpenicillin 125mg/5ml Oral doctor tells you to stop, your condition may Reconstituted solution: Store up to 7 days in a Phenoxymethylpenicillin is indicated for Solution contains 2.80g of sucrose per 5ml dose. re-occur or get worse. If you have any further refrigerator. prophylaxis against: Phenoxymethylpenicillin 250mg/5ml Oral questions on the use of this medicine, ask your Do not throw away any medicines via • Pneumococcal Infection (e.g. in asplenia and Solution contains 2.89g of sucrose per 5ml dose. doctor or pharmacist or nurse. wastewater or household waste. Ask your in patients with sickle cell disease). • This should be taken into account in patients pharmacist how to throw away medicines you no with diabetes mellitus. May be harmful to teeth. longer use. These measures will help protect the • If you have been told by your doctor that you 4. POSSIBLE SIDE EFFECTS environment. WHAT YOU NEED TO KNOW BEFORE have an intolerance to some sugars, contact If your doctor tells you to stop your treatment, YOU TAKE your doctor before taking this medicinal product. return any left over to the pharmacist. Only keep PHENOXYMETHYLPENICILLIN Potassium Like all medicines this medicine can cause side it if your doctor tells you to. ORAL SOLUTION Phenoxymethylpenicillin 125mg/5ml Oral Solution effects, although not everybody gets them. 2. contains 14.2mg of potassium per 5ml dose. Do not take Phenoxymethylpenicillin Oral Phenoxymethylpenicillin 250mg/5ml Oral Solution STOP taking the medicine and tell your CONTENTS OF THE PACK AND Solution if: contains 28.4mg of potassium per 5ml dose. doctor IMMEDIATELY if you experience any of 6. OTHER INFORMATION • You ever had a bad reaction or allergic • This should be taken into account by patients the following: • an allergic reaction - symptoms may include: reaction to any Phenoxymethylpenicillin or with reduced kidney function or patients on a What Phenoxymethylpenicillin Oral Solution shortness of breath, skin rash or itching, hives, Cephalosporin-type antibiotic. An example of a controlled potassium diet. contains Cephalosporin-type antibiotic is Cefradine. Sodium benzoate swelling of the skin (especially of the lips, face Each 5ml spoonful of oral solution contains • You are allergic to any of the ingredients • Sodium benzoate may increase jaundice or tongue), chills or fever, painful joints 125mg or 250mg of phenoxymethylpenicillin as • contained in this medicine. (yellowing of the skin and eyes) in newborn severe peeling/blistering of the skin phenoxymethylpenicillin potassium. It also • • You are taking methotrexate (a cytotoxic drug babies (up to 4 weeks old). This medicine seizures contains sodium benzoate, saccharin sodium, • used to treat cancers and psoriasis) contains 16 mg sodium benzoate in each 5ml profuse watery diarrhoea usually with blood trusil orange flavour, orange colour (containing dose which is equivalent to 320mg/100ml bottle. and mucus, stomach pain and fever sunset yellow (E110) and ponceau 4R (E124)) Take special care with your medicine if: Sodium and sucrose. • You suffer from any stomach problems, e.g. • This medicine contains less than 1 mmol The following are the more common effects. vomiting sodium (23mg) per 5 ml dose, that is to say Tell your doctor or pharmacist if they worry What Phenoxymethylpenicillin Oral Solution • You suffer from any kidney problems essentially “sodium free”. you. looks like and contents of the pack • You suffer from allergies and/or asthma E124 & E110 • stomach pain or cramps, nausea (feeling sick), Dry powder: an off white pale pink granular Ponceau 4R (E124) and sunset yellow (E110) vomiting (being sick) and diarrhoea powder. Taking other medicines may cause allergic type reactions. Reconstituted solution: a clear orange solution Your medicine may interfere with other The following are other possible side effects: with an orange odour and flavour. medicines that you may be taking. Please inform HOW TO TAKE Mouth Phenoxymethylpenicillin Oral Solution is your doctor or pharmacist if you are taking, or PHENOXYMETHYLPENICILLIN ORAL • sore mouth available in size 100ml on reconstitution. have recently taken any other medicines even SOLUTION • black hairy tongue those not prescribed. 3. • sore throats The product licence holder and manufacturer How much of your medicine to take • teeth may appear stained, usually returning to is: Athlone Laboratories Limited, Talk to your doctor or pharmacist or nurse before Always take this medicine exactly as your doctor normal with brushing (this has been reported in Ballymurray, Co. Roscommon, Ireland. taking: or pharmacist has told you, check with your children).
Load more

Recommended publications
  • Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction
    Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e494-504. Amoxicillin in the prevention of infectious complications after tooth extraction Journal section: Oral Surgery doi:10.4317/medoral.21139 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.21139 Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis María-Iciar Arteagoitia 1, Luis Barbier 2, Joseba Santamaría 3, Gorka Santamaría 4, Eva Ramos 5 1 MD, DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 2 MD PhD, Chair Professor, Maxillofacial Surgery Department, BioCruces Health Research Institute, Cruces University Hos- pital, University of the Basque Country (UPV/EHU), Spain; Consolidated research group (UPV/EHU IT821-13) 3 MD, DDS, PhD, Professor and Chair, Maxillofacial Surgery Department, Bio Cruces Health Research Institute, Cruces University Hospital, University of the Basque Country (UPV/EHU), Bizkaia, Spain; Consolidated research group (UPV/EHU IT821-13) 4 DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 5 PhD, Degree in Farmacy, BioCruces Health Research Institute, Cruces University Hospital. Spain Correspondence: Servicio Cirugía Maxilofacial Hospital Universitario de Cruces Plaza de Cruces s/n Arteagoitia MI, Barbier L, Santamaría J, Santamaría G, Ramos E. Ef- Barakaldo, Bizkaia, Spain ficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention [email protected] of infection and dry socket after third molar extraction.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Augmentin 125 mg/31.25 mg/5 ml powder for oral suspension Augmentin 250 mg/62.5 mg/5 ml powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 25 mg amoxicillin and potassium clavulanate equivalent to 6.25 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 50 mg amoxicillin and potassium clavulanate equivalent to 12.5 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for oral suspension. Off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Augmentin is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis 2 • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis • Bone and joint infections, in particular osteomyelitis.
    [Show full text]
  • Ceftaroline in the Management of Complicated Skin and Soft Tissue Infections and Community Acquired Pneumonia
    Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Year: 2015 Volume: 11 Therapeutics and Clinical Risk Management Dovepress Running head verso: Mpenge and MacGowan Running head recto: Ceftaroline in the management of cSSTI and CAP open access to scientific and medical research DOI: http://dx.doi.org/10.2147/TCRM.S75412 Open Access Full Text Article REVIEW Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia Mbiye A Mpenge¹ Abstract: Ceftaroline is a new parenteral cephalosporin approved by the European Medicines Alasdair P MacGowan² Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of com- plicated skin and soft tissue infections (cSSTIs) including those due to methicillin-resistant ¹Department of Medical Microbiology, University Hospitals Bristol NHS Staphylococcus aureus (MRSA), and community-acquired pneumonia (CAP). Ceftaroline has Trust, Bristol Royal Infirmary, Bristol, broad-spectrum activity against gram-positive and gram-negative bacteria and exerts its bacteri- England; ²Department of Medical Microbiology, North Bristol NHS cidal effects by binding to penicillin-binding proteins (PBPs), resulting in inhibition of bacterial Trust, Southmead Hospital, Bristol, cell wall synthesis. It binds to PBP 2a of MRSA with high affinity and also binds to all six PBPs England in Streptococcus pneumoniae. In in vitro studies, ceftaroline demonstrated potent activity against Staphylococcus aureus (including MRSA and vancomycin-intermediate isolates), Streptococ- For personal use only. cus pneumoniae (including multidrug resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, and many common gram-negative pathogens, excluding extended spectrum beta- lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa. In Phase II and Phase III clinical trials, ceftaroline was noninferior to its comparator agents and demonstrated high clinical cure rates in the treatment of cSSTIs and CAP.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Eml-2017-Antibacterials-Eng.Pdf
    Consideration of antibacterial medicines as part of the revisions to 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee, 2017 and this summary should be read in conjunction with the full report (WHO Technical Report Series, No. 1006; http://apps.who.int/iris/bitstream/10665/259481/1/9789241210157-eng.pdf?ua=1). The revised lists of essential medicines (in English) are available as follows: 2017 WHO Model List of Essential Medicines for adults (EML) http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amend edAug2017.pdf?ua=1 2017 Model List of Essential Medicines for children (EMLc) http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017_FINAL_amend edAug2017.pdf?ua=1 Summary of changes to Section 6.2 Antibacterials: Section 6 of the EML covers anti-infective medicines. Disease-specific subsections within Section 6, such as those covering medicines for tuberculosis, HIV, hepatitis and malaria, have been regularly reviewed and updated, taking into consideration relevant WHO treatment guidelines.
    [Show full text]
  • Sinusitis (Acute): Antimicrobial Prescribing
    Sinusitis (acute): antimicrobial prescribing NICE guideline Published: 27 October 2017 www.nice.org.uk/guidance/ng79 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Sinusitis (acute): antimicrobial prescribing (NG79) Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 2 of conditions#notice-of-rights).
    [Show full text]
  • Package Leaflet
    PACKAGE LEAFLET Package leaflet: Information for the user Phenoxymethylpenicillin Sugar Free 125mg / 5ml Powder for Oral Solution Phenoxymethylpenicillin Sugar Free 250mg / 5ml Powder for Oral Solution (Phenoxymethylpenicillin) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Phenoxymethylpenicillin Sugar Free Oral Solution is and what it is used for 2. What you need to know before you take Phenoxymethylpenicillin Sugar Free Oral Solution 3. How to take Phenoxymethylpenicillin Sugar Free Oral Solution 4. Possible side effects 5. How to store Phenoxymethylpenicillin Sugar Free Oral Solution 6. Contents of the pack and other information 1. What Phenoxymethylpenicillin Sugar Free Oral Solution is and what it is used for Phenoxymethylpenicillin Sugar Free Oral Solution is available in two strengths as a powder for reconstitution. The strength you are given will be decided by your doctor. Phenoxymethylpenicillin, the active ingredient, is an antibiotic, which belongs to a group of medicines called penicillins, which are used to kill bacteria that cause infections in your body. Your medicine is used to: treat bacterial infections of the ear, throat, respiratory tract, skin and soft tissues prevent infections such as rheumatic fever or chorea recurring prevent pneumococcal infection (e.g.
    [Show full text]
  • Vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    antibiotics Review Short- vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of Randomized Controlled Trials Anna Engell Holm * , Carl Llor, Lars Bjerrum and Gloria Cordoba Research Unit for General Practice and Section of General Practice, Department of Public Health, Øster Farimagsgade 5, 1014 Copenhagen, Denmark; [email protected] (C.L.); [email protected] (L.B.); [email protected] (G.C.) * Correspondence: [email protected]; Tel.: +45-261-110-54 Received: 9 September 2020; Accepted: 21 October 2020; Published: 26 October 2020 Abstract: BACKGROUND: To evaluate the effectiveness of short courses of antibiotic therapy for patients with acute streptococcal pharyngitis. METHODS: Randomized controlled trials comparing short-course antibiotic therapy ( 5 days) with long-course antibiotic therapy ( 7 days) for patients with ≤ ≥ streptococcal pharyngitis were included. Two primary outcomes: early clinical cure and early bacterial eradication. RESULTS: Fifty randomized clinical trials were included. Overall, short-course antibiotic treatment was as effective as long-course antibiotic treatment for early clinical cure (odds ratio (OR) 0.85; 95% confidence interval (CI) 0.79 to 1.15). Subgroup analysis showed that short-course penicillin was less effective for early clinical cure (OR 0.43; 95% CI, 0.23 to 0.82) and bacteriological eradication (OR 0.34; 95% CI, 0.19 to 0.61) in comparison to long-course penicillin. Short-course macrolides were equally effective, compared to long-course penicillin. Finally, short-course cephalosporin was more effective for early clinical cure (OR 1.48; 95% CI, 1.11 to 1.96) and early microbiological cure (OR 1.60; 95% CI, 1.13 to 2.27) in comparison to long-course penicillin.
    [Show full text]
  • Enzymatic Synthesis of Phenoxymethylpenicillin Using Erwinia Aroideae Enzyme
    VOL. XXXVII NO. 10 THE JOURNAL OF ANTIBIOTICS 1217 ENZYMATIC SYNTHESIS OF PHENOXYMETHYLPENICILLIN USING ERWINIA AROIDEAE ENZYME Doo H. NAM and DEWEY D. Y. RYut* The Korea Advanced Institute of Science, Seoul, Korea 'University of California , Davis, CA 95616, USA (Received for publication February 21, 1984) Enzymatic synthesis of phenoxymethylpenicillin from 6-aminopenicillanic acid and pheno- xyacetic acid methyl ester was attempted by using partially purified a-acylamino-s-lactam acylhydrolase I (ALAHase I) enzyme from Enrinia aroideae NRRL B-138. The reaction rates were carefully followed by determination of 6-aminopenicillanic acid (6-APA), phenoxy- methylpenicillin (PNV), phenoxyacetic acid (POA), phenoxyacetic acid methyl ester (POM), and phenoxyacetylglycine (POG) using high performance liquid chromatography. Among the acyl donors tested, POM gave the highest yield (12.2% based on 6-APA). The overall con- version increased almost linearly with an increase in molar ratio of POM to 6-APA up to 4: 1. The effects of organic solvents on the overall yield were also evaluated. Some improvement of PNV yield was observed when ethanol, 2-propanol, and acetone were used. ALAHase I was found to carry out three reactions simultaneously: transfer of acyl group to acyl acceptor to form semisynthetic -lactam antibiotic; hydrolysis of acyl donor in amide or ester bond, and hydrolysis of semisynthetic lactam antibiotic which was produced by the enzyme. It was also observed that the hydrolysis reactions of POM and PNV were irreversible in this reaction system. The optimal pH for the three reactions was different. They were: pH 9.0 for POM hydrolysis, 6.8 for the transfer of phenoxyacetyl group to 6-APA, and 6.0 for the PNV hydro- lysis.
    [Show full text]
  • Pneumonia (Community-Acquired): Antimicrobial Prescribing
    DRAFT FOR CONSULTATION 1 Pneumonia (community-acquired): 2 antimicrobial prescribing 3 NICE guideline 4 Draft for consultation, February 2019 This guideline sets out an antimicrobial prescribing strategy for community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations in this guideline are for the use of antibiotics to manage community-acquired pneumonia in adults, young people and children. It does not cover diagnosis. See the NICE guideline on pneumonia in adults for other recommendations on diagnosis and management of community-acquired pneumonia, including microbiological tests. For managing other lower respiratory tract infections (including hospital-acquired pneumonia), see our web page on respiratory conditions. See a 3-page visual summary of the recommendations, including tables to support prescribing decisions. Who is it for? • Health care professionals • People with community-acquired pneumonia, their families and carers The guideline contains: • the draft recommendations • summary of the evidence. Information about how the guideline was developed is on the guideline’s page on the NICE website. This includes the full evidence review, details of the committee and any declarations of interest. Community-acquired pneumonia: antimicrobial prescribing guidance Page 1 of 30 DRAFT FOR CONSULTATION 1 Recommendations 2 1.1 Managing community-acquired pneumonia 3 Treatment for adults 4 1.1.1 Offer an antibiotic(s) for adults with community-acquired 5 pneumonia within 4 hours of
    [Show full text]
  • The Efficacy and Safety of Short Course Therapy with Cefixime in URTI In
    IP Journal of Otorhinolaryngology and Allied Science 2020;3(3):81–85 Content available at: https://www.ipinnovative.com/open-access-journals IP Journal of Otorhinolaryngology and Allied Science Journal homepage: www.ipinnovative.com Original Research Article The efficacy and safety of Short course therapy with Cefixime in URTI in Indian Scenario Ketan Pakhale1, G K Tandon2, Tanmay Bansal3, Vineet Jain4, Dhiraj Dhoot5,*, Saiprasad Patil5, Hanmant Barkate5 1Dept. of ENT Surgeon, Metabol Clinic, 12, Harsha Apts., Amrut Nagar, Ghatkopar (W), Mumbai, Maharashtra, India 2ENT Clinic, F123-A, Dilshad Colony, Delhi, India 3Samvedna ENT Clinic, Dilsha Colony, Delhi, India 4Chief ENT Surgeon, Kota, Rajasthan, India 5Global Medical Affairs (IF), Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India ARTICLEINFO ABSTRACT Article history: Upper respiratory tract infections (URTI) are one of the commonest cause for a patient’s visit to outpatient Received 22-05-2020 department (OPD). Short course therapies with penicillin and cephalosporin class of antibiotics are Accepted 16-06-2020 commonly prescribed in URTI cases. This study was a retrospective, multicentre, observational cohort Available online 24-10-2020 analysis, planned to evaluate the effectiveness and safety of Cefixime 400 mg per day in patients of URTI, using WURSS 21 score. We analysed the data of 200 patients who were prescribed Cefixime for URTI. Most of the patients (55%) were male. The baseline mean WURSS score of 41.09 33.45 decreased to Keywords: 25.74 22.29 [(-37.3%), p value<0.05] at visit 2; moreover, it further decreased to 5.75 6.75 [(-86.0%), URTI p value<0.05] at visit 3.
    [Show full text]